US 9,518,085 B2 · Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases

AssigneeCentro de Ingenieria Genetica y Biotechnologia

InventorsGiselle Penton Rol, Alexey Llopiz Arzuaga, Javier Marin Prida, Eduardo Penton Arias, Efrain Rodriguez Jimenez, Alexis Musacchio Lasa, Vladimir Armando Besada Perez, Gilberto Lazaro Pardo Andreu, Luis Javier Gonzalez Lopez, Nancy Pavon Fuentes, Gerardo Enrique Guillen Nieto, Pedro Antonio Lopez Saura

Life of this patent

Estimating the term…

Abstract

The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their use for ischemic or neurodegenerative CNS disease treatment.

Claims7

Dependent claims

A pharmaceutical combination characterized by its components having a synergic effect and comprising a first component consisting of (i) any of the chromogenic peptides identified as SEQ ID NO:2-SEQ ID NO:5 (PCB-aa) or (ii) phycocyanobilin (PCB), and a second component selected from the group consisting of interferon beta, Interleukin-2 (IL-2), Erythropoietin (EPO), asyaloEPO and Peptide secretagogue of the human growth hormone (GHRP-6).

Dependencies are inferred from the claim text.

Facts

Application

14/127,369Filed 29 Jun 2012

Priority

CU 2011/01461 Jul 2011

Published

US 2014/0356319 A14 Dec 2014

Granted

13 Dec 2016

Term ends

Not estimatedThe source records don’t support an estimate.

Classification24 codes

A61K 31/409
Having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil: having four such…
A61K 38/06
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tripeptides
A61K 38/07
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: tetrapeptides
A61K 38/08
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof: peptides having 5 to 11 amino acids